- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07397936
Rebamipide versus Diquafosol und Cyclosporin bei perioperativem Trockenem Auge in der Kataraktchirurgie
Rebamipid versus Diquafosol-Cyclosporin bei perioperativer Trockener-Augen-Erkrankung in der Kataraktchirurgie: Eine randomisierte Studie
The goal of this clinical trial is to compare the efficacy of 2% rebamipide monotherapy versus a combination therapy of 3% diquafosol and 0.05% cyclosporine for the management of dry eye disease in patients undergoing cataract surgery. It will also evaluate the safety and ocular surface stability effects of these treatments during the perioperative period.
The main questions it aims to answer are:
Does rebamipide monotherapy maintain tear film breakup time (TBUT) and prevent corneal damage as effectively as the combination therapy after surgery? How do patient symptoms (OSDI scores) and inflammation markers (MMP-9) change with each treatment?
Researchers will compare the rebamipide group to the diquafosol-cyclosporine combination group to evaluate their effects on perioperative dry eye management.
Participants will:
Use the assigned study eye drops starting 1 month before their cataract surgery and continuing for 3 months after surgery.
Visit the clinic for eye examinations at baseline, the day of surgery, and at 1 week, 1 month, and 3 months postoperatively.
Undergo tests including tear film breakup time measurement, corneal staining, Schirmer's test, and tear MMP-9 level assessments.
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
Dry eye disease (DED) is common in patients undergoing cataract surgery and may worsen during the perioperative period, leading to ocular discomfort and delayed visual recovery. Pharmacologic treatments targeting tear film instability and ocular surface inflammation are therefore important in perioperative management.
This prospective, randomized, parallel-group clinical trial compared two perioperative treatment strategies for DED in patients scheduled for cataract surgery. Eligible participants with pre-existing dry eye disease were randomized in a 1:1 ratio to receive either topical rebamipide 2% monotherapy or combination therapy with topical diquafosol 3% and cyclosporine 0.05%. Study medications were initiated 1 month prior to surgery and continued for 3 months postoperatively.
The primary outcome measure was the change in tear film breakup time (TBUT) during the early postoperative period. Secondary outcome measures included changes in corneal staining graded by the Oxford scale, patient-reported symptoms assessed by the Ocular Surface Disease Index (OSDI), tear secretion measured by Schirmer's test, and ocular surface inflammation evaluated using a tear matrix metalloproteinase-9 (MMP-9) point-of-care immunoassay.
Clinical assessments were performed at baseline, on the day of surgery, and at postoperative week 1, month 1, and month 3. Safety was evaluated by monitoring intraoperative and postoperative adverse events throughout the study period.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 4
Kontakte und Standorte
Studienorte
-
-
Seoul
-
Seoul, Seoul, Südkorea
- Samsung Medical Center
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
-
Adults scheduled for cataract surgery
-
Presence of dry eye disease, defined as an Ocular Surface Disease Index (OSDI) score ≥12 and at least one of the following:
- Tear film breakup time (TBUT) ≤7 seconds
- Oxford corneal staining grade ≥1
- Schirmer's test value ≤10 mm/5 min
-
Ability and willingness to comply with the study protocol and follow-up schedule
-
Provision of written informed consent
Exclusion Criteria:
- Presence of ocular surface or ocular conditions that could affect dry eye status (e.g., active keratitis or ocular infection)
- Use of topical intraocular pressure-lowering medications
- History of ocular surgery other than cataract surgery in the study eye
- Any systemic or ocular condition judged by the investigator to interfere with study participation or outcome assessment
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Group R
Participants receive topical rebamipide 2% ophthalmic solution four times daily, initiated 1 month before cataract surgery and continued for 3 months postoperatively. |
Topical administration, four times daily |
|
Aktiver Komparator: Group DC
Participants receive topical diquafosol 3% ophthalmic solution four times daily in combination with cyclosporine 0.05% ophthalmic solution twice daily, initiated 1 month before cataract surgery and continued for 3 months postoperatively. |
Topical administration, four times daily Topical administration, two times daily |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change in Tear Film Breakup Time (TBUT)
Zeitfenster: From baseline to postoperative week 1
|
Change in tear film breakup time (TBUT) from baseline and during the early postoperative period following cataract surgery, comparing rebamipide monotherapy with diquafosol-cyclosporine combination therapy. |
From baseline to postoperative week 1
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change in Ocular Surface Disease Index (OSDI) Score
Zeitfenster: From baseline to 1 and 3 months postoperatively
|
Change in patient-reported ocular symptoms assessed using the Ocular Surface Disease Index (OSDI) questionnaire, comparing rebamipide monotherapy with diquafosol-cyclosporine combination therapy. The OSDI score ranges from 0 to 100, with higher scores indicating more severe ocular surface symptoms (worse outcomes). |
From baseline to 1 and 3 months postoperatively
|
|
Change in Corneal Staining Grade (Oxford Scale)
Zeitfenster: From baseline to postoperative week 1, and to 1 and 3 months postoperatively
|
Change in corneal epithelial staining graded using the Oxford grading scale (0-5) following fluorescein staining, comparing ocular surface staining severity between treatment groups. Higher grades indicate more severe corneal epithelial staining (worse outcomes). |
From baseline to postoperative week 1, and to 1 and 3 months postoperatively
|
|
Change in Schirmer's Test Value
Zeitfenster: From baseline to 1 and 3 months postoperatively
|
Change in tear secretion measured by Schirmer's test without anesthesia, comparing tear production between rebamipide monotherapy and diquafosol-cyclosporine combination therapy. |
From baseline to 1 and 3 months postoperatively
|
|
Change in Tear Matrix Metalloproteinase-9 (MMP-9) Level
Zeitfenster: From baseline to 1 and 3 months postoperatively
|
Change in tear matrix metalloproteinase-9 (MMP-9) levels assessed using a point-of-care immunoassay (InflammaDry), comparing ocular surface inflammation between treatment groups. |
From baseline to 1 and 3 months postoperatively
|
Mitarbeiter und Ermittler
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Augenkrankheiten
- Erkrankungen des Tränenapparates
- Linsenkrankheiten
- Katarakt
- Syndrome des trockenen Auges
- Pharmazeutische Lösungen
- Peptide
- Aminosäuren, Peptide und Proteine
- Pharmazeutische Präparate
- Pharmakologische Maßnahmen
- Chemische Handlungen und Verwendung
- Therapeutische Anwendungen
- Polycyclische Verbindungen
- Lösungen
- Spezialzwecke von Chemikalien
- Makrocyclische Verbindungen
- Peptide, zyklisch
- Cyclosporine
- Cyclosporin
- Ophthalmologische Lösungen
- Rebamipid
- Diquafosol
Andere Studien-ID-Nummern
- SMC RVK Trial I
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
The detailed study protocol and the data that support the findings of this study are available from the corresponding author upon reasonable request.
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .